Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Amir T. Fathi, Aleksandra Filipovic, Keri Maher, Dale G Schaar, Rabin Niroula, Joseph J. Maly, Deepa Jaykumar, Noah Merin, Jay Yang, Jorge R. Galvez Silva, Varun Gang, Taylor Meeks, Christopher Korth, Guenther Koehne

Blood (2024) 144 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2024-209848

Published: 2024

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz

Blood (2023) 142 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2023-189700

Published: 2023

Journal Articles

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Joaquin Martinez-Lopez, Guenther Koehne, Paula Rodriguez Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T Sullivan, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2023-182130

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

Polatuzumab- Rituximab with or without Bendamustine As Second-Line Therapy for Relapsed Refractory Large B-Cell Lymphomas: Single Center Experience

Ariel Perez Perez, Shreya Saxena, Tiba Al Sagheer, Muni Rubens, Talia Zahra, George Nahas, Alex V. Mejia Garcia, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Atulya Khosla, Manmeet Ahluwalia, Guenther Koehne, Yuliya P.L. Linhares

Blood (2022) 140 (Supplement 1): 6672–6673.

https://doi.org/10.1182/blood-2022-163461

Published: 2022

Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel

Blood (2022) 140 (Supplement 1): 12973–12975.

https://doi.org/10.1182/blood-2022-165289

Published: 2022

Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Blood (2022) 140 (Supplement 1): 391–393.

https://doi.org/10.1182/blood-2022-162440

Published: 2022

Journal Articles

Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in

Yuliya Linhares, Ariel Perez Perez, Tiba Al Sagheer, George Nahas, Alex Mejia-Garcia, Muni Rubens, Talia Zahra, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Yazmin Odia, Guenther Koehne

Blood (2022) 140 (Supplement 1): 12061–12063.

https://doi.org/10.1182/blood-2022-167064

Published: 2022

Journal Articles

Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy

Monica Tadros, PharmD, Guenther Koehne, MDPhD, Talia Zahra, MD, Jessica Unzaga, PharmD, Moe Shwin, Nicholas Chow

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141276

Published: 2020

Journal Articles

Pre-Salvage ISS and Other Important Outcome Predictors in CD34 Selected Allogeneic Hematopoietic Cell Transplant for Multiple Myeloma

Adam Bryant, MD MSc, Patrick Hilden, MS, Sergio Giralt, MD, Miguel-Angel Perales, MD, Guenther Koehne, MD PhD

Blood (2018) 132 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2018-99-118625

Published: 2018

Journal Articles

Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma

Lizamarie Bachier Rodriguez, MD, Gunjan L. Shah, MD, Andrea Knezevic, MS, Sean M Devlin, PhD, Molly Maloy, MS, Guenther Koehne, MD PhD, David J. Chung, MD PhD, Heather J. Landau, MD, Sergio Giralt, MD

Blood (2018) 132 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2018-99-119537

Published: 2018

Journal Articles

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Gunjan L. Shah, MD, Heather Landau, MD, Caitlin Sarubbi, A.B, Ryan Schofield, MS, Andrew Lin, PharmD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Sean M. Devlin, PhD, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD

Blood (2017) 130 (Supplement 1): 3296.

https://doi.org/10.1182/blood.V130.Suppl_1.3296.3296

Published: 2017

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Benefits Patients with Persistent Disease and Results in a High Rate of Residual Disease Clearance

Bartlomiej Getta, FRCPA, FRACP, MBBS, Mikhail Roshal, MDPhD, Guenther Koehne, MDPhD

Blood (2017) 130 (Supplement 1): 2001.

https://doi.org/10.1182/blood.V130.Suppl_1.2001.2001

Published: 2017

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Irene Rodriguez-Sanchez, Aisha N. Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Boglarka Gyurkocza, MD, Nancy A. Kernan, MD, Guenther Koehne, MDPhD, Esperanza B. Papadopoulos, MD, Doris Ponce, MD, Craig S. Sauter, MD, Virginia Escobedo, RN, Victoria Szenes, PNP, Karim Baroudy, BS, Alison Slocum, MA, Richard J. O'Reilly, MD

Blood (2017) 130 (Supplement 1): 747.

https://doi.org/10.1182/blood.V130.Suppl_1.747.747

Published: 2017

Journal Articles

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Neha Korde, MD, Sham Mailankody, MBBS, Eric L Smith, MDPhD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Alexander Lesokhin, MD, Malin Hultcrantz, MD, David J. Chung, MDPhD, Gunjan L. Shah, MD, Guenther Koehne, MDPhD, Heather Landau, MD, Mikhail Roshal, MDPhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Donna Mastey, RN, Nicole Evancha, Sean M. Devlin, PhD, Ola Landgren, MD PhD

Blood (2017) 130 (Supplement 1): 3133.

https://doi.org/10.1182/blood.V130.Suppl_1.3133.3133

Published: 2017

Journal Articles

Targeting WT1 in hematologic malignancies?

Guenther Koehne

Blood (2017) 130 (18): 1959–1960.

https://doi.org/10.1182/blood-2017-09-805358

Published: 2017

Journal Articles

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Aisha N Hasan, MD, Parastoo B Dahi, MD, Sergio Giralt, MD, Guenther Koehne, MD PhD, Nancy A. Kernan, MD, Esperanza B Papadopoulos, MD, Rachel Lehrman, Irene Rodriguez-Sanchez, Richard J. O'Reilly, MD

Blood (2016) 128 (22): 61.

https://doi.org/10.1182/blood.V128.22.61.61

Published: 2016

NARROW

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Polatuzumab- Rituximab with or without Bendamustine As Second-Line Therapy for Relapsed Refractory Large B-Cell Lymphomas: Single Center Experience

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in

Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy

Pre-Salvage ISS and Other Important Outcome Predictors in CD34 Selected Allogeneic Hematopoietic Cell Transplant for Multiple Myeloma

Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Benefits Patients with Persistent Disease and Results in a High Rate of Residual Disease Clearance

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Targeting WT1 in hematologic malignancies?

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only